Equities

LivaNova PLC

LivaNova PLC

Actions
  • Price (USD)55.53
  • Today's Change0.43 / 0.78%
  • Shares traded553.33k
  • 1 Year change+15.23%
  • Beta0.9308
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.

  • Revenue in USD (TTM)1.15bn
  • Net income in USD17.55m
  • Incorporated2015
  • Employees2.90k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Owens & Minor, Inc.10.33bn-41.30m1.85bn13.70k--2.007.510.1788-0.5479-0.5479136.3112.071.976.7215.18754,304.20-0.78821.32-1.182.0720.5616.48-0.39970.56140.52442.040.69440.7983.801.87-284.47--25.91--
Conmed Corp1.26bn82.35m1.91bn4.00k23.70--12.351.512.612.6139.97--------315,387.00--0.8972--1.0254.9454.956.531.65--3.76--139.1619.067.68179.9910.042.890.00
Helen of Troy Limited2.00bn162.04m2.16bn1.90k13.431.3610.251.086.766.7683.2766.810.65792.254.131,051,199.005.338.626.4610.8245.9543.168.109.720.97554.820.3168---6.786.98-35.97-0.48866.65--
Inari Medical Inc493.63m-1.64m2.21bn1.30k--4.73419.984.47-0.0318-0.03188.608.050.83781.577.67379,716.90-0.2777-0.5941-0.3129-0.669688.0389.06-0.3314-0.62952.52--0.00--28.73135.4094.41--52.46--
STAAR Surgical Co322.42m21.35m2.29bn1.06k108.455.9386.057.110.43240.43246.537.900.71062.354.10305,317.304.706.775.407.9078.3676.896.629.165.08--0.00050.0013.3721.07-46.1833.8551.95--
ICU Medical Inc2.26bn-29.66m2.30bn14.00k--1.0711.511.02-1.23-1.2393.5587.960.50802.1611.79161,366.10-0.66691.46-0.74911.6532.7534.11-1.312.231.060.64840.43450.00-0.915410.0460.08---1.45--
Patterson Companies, Inc.6.57bn193.86m2.31bn7.60k12.722.398.250.3522.032.0368.8610.782.235.6114.48864,047.906.580.370211.300.565521.3021.052.950.18110.724312.080.4462846.10-0.42983.442.1410.798.220.00
Tandem Diabetes Care Inc747.72m-222.61m2.33bn2.40k--7.43--3.12-3.44-3.4411.514.780.74572.826.79311,549.20-22.20-10.08-27.07-12.2349.1751.77-29.77-11.593.02--0.4761---6.6832.39-135.33--76.81--
Premier Inc1.32bn167.33m2.49bn2.80k14.931.048.481.891.391.3910.9719.950.35714.573.06470,033.204.4210.395.6713.0067.1362.0412.3722.601.32516.340.243119.11-6.762.44-34.17-15.30-2.29--
Procept Biorobotics Corp136.19m-105.90m2.66bn626.00--9.45--19.56-2.24-2.242.885.530.38151.914.28217,557.50-29.66---33.47--52.17---77.75--6.77--0.1546--81.55---21.51------
TransMedics Group Inc241.62m-25.03m2.93bn584.00--21.25--12.13-0.7685-0.76857.434.200.49152.705.30413,738.00-5.09-16.08-5.53-17.9563.7765.37-10.36-40.478.49--0.7868--158.5379.3630.92--225.12--
LivaNova PLC1.15bn17.55m2.97bn2.90k171.002.3343.812.580.32220.322221.3223.700.48832.765.79397,774.100.7472-6.010.8627-7.4266.8666.991.53-13.562.511.100.3147--12.890.8278120.34---1.64--
Enovis Corp1.71bn-54.37m3.02bn6.55k--0.8818.511.77-0.9987-0.611731.3362.610.38881.596.11260,640.80-1.23-0.3569-1.37-0.4158.2148.19-3.15-1.061.161.020.1199--9.22-4.89-40.29--11.91--
Axonics Inc366.38m-6.09m3.39bn797.00--5.30532.279.26-0.1285-0.12857.4312.560.53131.357.18459,697.60-0.8828-12.67-0.9601-13.7674.9470.04-1.66-29.688.98--0.00--33.86249.0689.80--23.65--
Envista Holdings Corp2.57bn-100.20m3.44bn12.80k--0.822697.191.34-0.6022-0.602214.6524.340.38913.996.41200,507.80-1.521.94-1.792.3456.5257.65-3.905.291.905.120.26610.00-0.1012-2.04-142.10---4.22--
Integer Holdings Corp1.63bn98.09m3.72bn10.50k38.542.4418.712.282.882.8847.8645.520.54524.924.95155,494.603.283.283.533.5326.5226.946.016.402.013.660.43030.0016.035.6238.719.3321.71--
Data as of Apr 26 2024. Currency figures normalised to LivaNova PLC's reporting currency: US Dollar USD

Institutional shareholders

48.72%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Dec 20236.46m11.97%
PRIMECAP Management Co.as of 31 Dec 20235.79m10.73%
Millennium Management LLCas of 09 Apr 20242.73m5.07%
Barrow, Hanley, Mewhinney & Strauss LLCas of 31 Dec 20232.37m4.40%
SSgA Funds Management, Inc.as of 31 Dec 20231.99m3.68%
The Vanguard Group, Inc.as of 31 Dec 20231.67m3.10%
AllianceBernstein LPas of 31 Dec 20231.54m2.86%
Columbia Management Investment Advisers LLCas of 31 Dec 20231.26m2.33%
Dimensional Fund Advisors LPas of 31 Dec 20231.24m2.30%
Greenlight Capital, Inc.as of 31 Dec 20231.23m2.28%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.